Clamp, A. R., Mäenpää, J., Cruickshank, D., Ledermann, J., Wilkinson, P. M., Welch, R., . . . Jayson, G. C. (2006). SCOTROC 2B: Feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer. Nature Publishing Group.
Citação norma ChicagoClamp, A R., et al. SCOTROC 2B: Feasibility of Carboplatin Followed By Docetaxel or Docetaxel–irinotecan As First-line Therapy for Ovarian Cancer. Nature Publishing Group, 2006.
Citação norma MLAClamp, A R., et al. SCOTROC 2B: Feasibility of Carboplatin Followed By Docetaxel or Docetaxel–irinotecan As First-line Therapy for Ovarian Cancer. Nature Publishing Group, 2006.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.